IQVIA Holdings Inc. $IQV Stock Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.1% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 326,418 shares of the medical research company's stock after selling 14,058 shares during the period. Assenagon Asset Management S.A. owned 0.20% of IQVIA worth $87,757,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IQV. BlackRock Inc. acquired a new position in IQVIA in the 2nd quarter worth about $2,811,292,000. Canada Pension Plan Investment Board bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $240,911,000. Bank of America Corp DE bought a new stake in shares of IQVIA in the 2nd quarter valued at approximately $235,551,000. Legal & General Group Plc acquired a new position in IQVIA in the second quarter worth approximately $211,342,000. Finally, Bank of New York Mellon Corp acquired a new position in IQVIA in the second quarter worth approximately $180,296,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Trading Down 1.5%

IQV stock opened at $267.00 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $277.40. The company has a market cap of $43.95 billion, a P/E ratio of 23.86, a PEG ratio of 2.35 and a beta of 1.17. The business has a fifty day moving average of $260.76 and a 200-day moving average of $212.85.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm's quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter last year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts expect that IQVIA Holdings Inc. will post 11.56 EPS for the current year.

Insiders Place Their Bets

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of IQVIA stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. The trade was a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company's stock, valued at $732,932.69. This represents a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock valued at $3,796,021 over the last three months. 1.70% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on IQV shares. UBS Group assumed coverage on shares of IQVIA in a research report on Wednesday, September 30th. They set a "buy" rating and a $345.00 price objective on the stock. William Blair raised shares of IQVIA to a "strong-buy" rating in a research report on Tuesday, July 28th. Royal Bank Of Canada increased their price target on shares of IQVIA from $247.00 to $319.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 29th. TD Cowen raised their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a "buy" rating in a report on Wednesday, July 29th. Finally, BMO Capital Markets lifted their price objective on shares of IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $276.00.

About IQVIA

IQVIA Holdings Inc NYSE: IQV is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA's offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.